Evidence map›Paper›PMID 28932494›Full record

ArticleInterventional medicine & applied science2017

Nanotechnology: Advancing the translational respiratory research.

Kamal Dua, Shakti Dhar Shukla, Terezinha de Jesus Andreoli Pinto, Philip Michael Hansbro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Interventional medicine & applied science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia.
Shakti Dhar ShuklaPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Newcastle, NSW, Australia.
Terezinha de Jesus Andreoli PintoDepartment of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Philip Michael HansbroPriority Research Centre for Healthy Lungs, Hunter Medical Research Institute, Newcastle, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Considering the various limitations associated with the conventional dosage forms, nanotechnology is gaining increased attention in drug delivery particularly in respiratory medicine and research because of its advantages like targeting effects, improved pharmacotherapy, and patient compliance. This paper provides a quick snapshot about the recent trends and applications of nanotechnology to various translational and formulation scientists working on various respiratory diseases, which can help paving a new path in developing effective drug delivery system.

Indexed as

drug deliverynanoparticulatenanotechnologyrespiratorytranslational

Identifiers

PMID28932494
PMCPMC5598120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.